A5037784199- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Cutaneous lymphoproliferative disorders research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- T-cell and Retrovirus Studies
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Algebraic Geometry and Number Theory
- Advanced Radiotherapy Techniques
- Vascular Tumors and Angiosarcomas
- Advanced Algebra and Geometry
- RNA modifications and cancer
- Medical Imaging Techniques and Applications
- Multiple Myeloma Research and Treatments
Hokkaido University
2021-2024
The University of Texas MD Anderson Cancer Center
2014-2023
The University of Tokyo
2001-2023
University of Duisburg-Essen
2021
Institute of Mathematics, Academia Sinica
2021
Jazz Pharmaceuticals (United States)
2020
Asahi Breweries (Japan)
2004-2016
John Wiley & Sons (United States)
2016
City Of Hope National Medical Center
2015
Sapporo Holdings (Japan)
2015
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.We conducted open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A+AVD) 670 bleomycin, (ABVD). The primary end point was modified progression-free survival (the time progression, death,...
Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell that arises around breast implants. The optimal management this disease has not been established. goal study to evaluate the efficacy different therapies used in patients with BI-ALCL determine an treatment approach.In study, we applied strict criteria pathologic findings, assessed used, and conducted clinical follow-up 87 BI-ALCL, including 50 previously reported literature 37 unreported. A Prentice,...
We report our experience with 129 cases of double hit lymphoma (DHL), defined as B-cell translocations and/or extra signals involving MYC plus BCL2 BCL6. All were reviewed for histopathological classification. Median age was 62 years (range, 18-85), 84% patients had advanced-stage disease, and 87% an International Prognostic Index score ≥2. Fourteen (11%) a history low-grade follicular lymphoma. translocation present in 81%, 25% patients. IGH-BCL2 12% Two-year event-free survival (EFS) rates...
Purpose The current classification systems of myelodysplastic syndromes (MDS), including the International Prognostic Scoring System (IPSS), do not fully reflect molecular heterogeneity disease. Molecular characterization may predict clinical outcome and help stratify patients for targeted therapies. Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective treatment MDS. Therefore, we investigated association between methylation in Patients Methods We...
PurposeFew studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients Hodgkin lymphoma (HL) and non-Hodgkin (NHL), especially treated contemporary techniques. These represent a unique group owing often large target volumes within mediastinum potential receive several lines chemotherapy that add pulmonary toxicity for relapsed or refractory disease. Our objective was determine incidence clinical dosimetric risk RP intensity modulated...
CUDC-907 is a first-in-class, oral small molecule inhibitor of both HDAC (class I and II) PI3K Iα, β, δ) enzymes, with demonstrated anti-tumor activity in multiple pre-clinical models, including MYC-driven ones. In this report, we present the safety preliminary results CUDC-907, without rituximab, patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL), particular focus on those MYC-altered disease. Thirty-seven DLBCL were enrolled, 14 confirmed Twenty-five received monotherapy...
To evaluate the safety and efficacy of panobinostat plus everolimus in patients with relapsed Hodgkin non-Hodgkin lymphoma. The concept was supported by single-agent clinical activity histone deacetylase inhibitors mTOR inhibitors, on vitro mechanism-based synergistic antiproliferative activity.This a phase I study or refractory lymphoma using orally Monday/Wednesday/Friday daily. Toxicity responses were assessed dose-escalation cohort followed expansion at maximum-tolerated dose....
Summary Survival outcome of patients with peripheral T‐cell lymphoma‐not otherwise specified ( PTCL ‐ NOS ) and angioimmunoblastic lymphoma AITL who experience disease progression/relapse remains very poor. A total 321 patients, newly diagnosed n = 180) or 141) between 1999 2015, were analysed. Failure‐free survival FFS overall OS calculated from the time first progression 1, 1), second 2, 2) third 3, 3). With a median follow‐up duration 52 months, 240 (135 , 105 experienced...
The purpose of this study was to report the response and toxicity ultra-low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL).We conducted a retrospective review patients with indolent mantle cell OAL treated 4 Gy orbit(s) in two 2-Gy fractions. Disease assessed clinically and/or radiographically at 2 4-month intervals after RT. Data collected included rates overall response, complete (CR), partial (PR), treatment-related toxic effects.Twenty-two (median age, 65 years) had...